Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
3281441 | Clinical Gastroenterology and Hepatology | 2016 | 33 Pages |
Abstract
Almost two-thirds of patients with CD refractory to at least 1 anti-TNF agent receive clinical benefit from ustekinumab therapy, not requiring steroids for up to 12 months afterward. While awaiting results from ongoing trials, ustekinumab can be considered for use in these patients.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Pauline Wils, Yoram Bouhnik, Pierre Michetti, Bernard Flourie, Hedia Brixi, Anne Bourrier, Matthieu Allez, Bernard Duclos, Jean-Charles Grimaud, Anthony Buisson, Aurélien Amiot, Mathurin Fumery, Xavier Roblin, Laurent Peyrin-Biroulet, Jérôme Filippi,